Abstract
The most common treatments for infectious diseases target the invading pathogen. The efficacy of such an approach may, however, be countered by the possibility of the development of resistance to a pharmacophore, through mutation(s) in pathogen molecules required for activity. Given the fact that pathogens exploit host factors in order to grow in an otherwise hostile environment, one possible way to circumvent the emergence of resistance is to develop drugs that target non-essential host factors hijacked by the pathogen, rather than the pathogen’s own molecules. Such solutions are already being developed for various viral and bacterial pathogens, but much less has been achieved with infections caused by protozoan parasites, as is the case of Plasmodium. Here, we highlight recent progress in host target-based anti-viral and anti-bacterial approaches and discuss possible host targets that may be used for anti-malarial interventions. Host molecules that play a role during either the liver or the blood stage of Plasmodium infection are outlined and their potential merits as anti-malarial targets are discussed.
Keywords: Malaria, Plasmodium, host factors, host targets, hepatitis C virus, liver-stage, blood-stage, drug resistance
Current Pharmaceutical Design
Title:Targeting Host Factors to Circumvent Anti-Malarial Drug Resistance
Volume: 19 Issue: 2
Author(s): Miguel Prudencio and Maria M. Mota
Affiliation:
Keywords: Malaria, Plasmodium, host factors, host targets, hepatitis C virus, liver-stage, blood-stage, drug resistance
Abstract: The most common treatments for infectious diseases target the invading pathogen. The efficacy of such an approach may, however, be countered by the possibility of the development of resistance to a pharmacophore, through mutation(s) in pathogen molecules required for activity. Given the fact that pathogens exploit host factors in order to grow in an otherwise hostile environment, one possible way to circumvent the emergence of resistance is to develop drugs that target non-essential host factors hijacked by the pathogen, rather than the pathogen’s own molecules. Such solutions are already being developed for various viral and bacterial pathogens, but much less has been achieved with infections caused by protozoan parasites, as is the case of Plasmodium. Here, we highlight recent progress in host target-based anti-viral and anti-bacterial approaches and discuss possible host targets that may be used for anti-malarial interventions. Host molecules that play a role during either the liver or the blood stage of Plasmodium infection are outlined and their potential merits as anti-malarial targets are discussed.
Export Options
About this article
Cite this article as:
Prudencio Miguel and M. Mota Maria, Targeting Host Factors to Circumvent Anti-Malarial Drug Resistance, Current Pharmaceutical Design 2013; 19 (2) . https://dx.doi.org/10.2174/1381612811306020290
DOI https://dx.doi.org/10.2174/1381612811306020290 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups
Current Cardiology Reviews Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better...
Current Pharmaceutical Design From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’
Mini-Reviews in Medicinal Chemistry Mechanisms of Esophageal Protection, Gastroprotection and Ulcer Healing by Melatonin. Implications for the Therapeutic use of Melatonin in Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease
Current Pharmaceutical Design Editorial [Hot Topic Cardiovascular and Metabolic Diseases: from Mechanisms to Novel Therapeutical Implications Guest Editors: Attila Borbély and Pawel Petkow Dimitrow]
Current Pharmaceutical Biotechnology Lack of Association between Genetic Polymorphism of Circadian Genes (PER2, PER3, CLOCK and OX2R) with Late Onset Depression and Alzheimer's Disease in a Sample of a Brazilian Population (Circadian Genes, Late-Onset Depression and Alzheimer's Disease)
Current Alzheimer Research PGC-1α: A Multifunctional Transcriptional Coactivator Involved in Human Metabolic Disorders
Current Genomics Analysis of QTc Interval during Levofloxacin Prescription in Cardiac Patients with Pneumonia
Current Drug Safety Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme
Current Medicinal Chemistry Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Inhibitory Effect of Ebselen on Cerebral Acetylcholinesterase Activity In Vitro: Kinetics and Reversibility of Inhibition
Current Pharmaceutical Design Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Novel Approaches to the Treatment of Obesity and Type 2 Diabetes Mellitus: Bioactive Leptin-Related Synthetic Peptide Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?
Current Vascular Pharmacology Intravenous Thrombolysis with rt-PA in Acute Stroke Patients Aged ≥80 Years
Letters in Drug Design & Discovery Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design Clinical and Molecular Perspectives of Monogenic Hypertension
Current Hypertension Reviews <i>In silico</i> Approach for Exploring the Role of AT1R Polymorphism on its Function, Structure and Drug Interactions
Current Computer-Aided Drug Design